Compare BCRX & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCRX | BRVE |
|---|---|---|
| Founded | 1986 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1995 | 2026 |
| Metric | BCRX | BRVE |
|---|---|---|
| Price | $7.20 | $20.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $20.45 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 4.5M | 473.2K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 381.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,186,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.23 | $16.70 |
| 52 Week High | $11.22 | $32.00 |
| Indicator | BCRX | BRVE |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 49.49 |
| Support Level | N/A | $17.52 |
| Resistance Level | $8.83 | $22.04 |
| Average True Range (ATR) | 0.37 | 1.76 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 0.87 | 67.28 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).